BMY-28100 IN RESPIRATORY TRACT INFECTION
スポンサーリンク
概要
- 論文の詳細を見る
We made a clinical study on BMY-28100, a new oral cephem antibiotic, in 12 patients with respiratory tract infection and obtained the following results.<BR>The overall clinical efficacy of BMY-28100 was good in 10, fair in 1 and poor in 1, and the efficacy rate was 83.3%.<BR>Two strains of <I>Staphylococcus aureus</I> and one of <I>Haemophilus influenzae</I> which were considered to be causative organisms were eradicated from the sputum after therapy. But one strain each of <I>Streptococcus pneumoniae, H. influenzae</I> and <I>Enterobacter cloacae</I> persisted.<BR>There were no clinical side effects but slight liver dysfunction was observed in one case.<BR>From these results, we consider BMY-28100 to be a useful drug for acute respiratory tract infection.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.